Content area
Abstract
In mammals, the white adipocyte is a cell type that is specialized for storage of energy (in the form of triacylglycerols) and for energy mobilization (as fatty acids). White adipocyte metabolism confers an essential role to adipose tissue in whole-body homeostasis. Dysfunction in white adipocyte metabolism is a cardinal event in the development of insulin resistance and associated disorders. This Review focuses on our current understanding of lipid and glucose metabolic pathways in the white adipocyte. We survey recent advances in humans on the importance of adipocyte hypertrophy and on the in vivo turnover of adipocytes and stored lipids. At the molecular level, the identification of novel regulators and of the interplay between metabolic pathways explains the fine-tuning between the anabolic and catabolic fates of fatty acids and glucose in different physiological states. We also examine the metabolic alterations involved in the genesis of obesity-associated metabolic disorders, lipodystrophic states, cancers and cancer-associated cachexia. New challenges include defining the heterogeneity of white adipocytes in different anatomical locations throughout the lifespan and investigating the importance of rhythmic processes. Targeting white fat metabolism offers opportunities for improved patient stratification and a wide, yet unexploited, range of therapeutic opportunities.
White adipocyte metabolism is important for the regulation of systemic metabolism and is often dysregulated in various conditions, such as cancer and type 2 diabetes mellitus. In this Review, Langin and colleagues provide an overview of lipid metabolism in white adipocytes and the related metabolism of glucose and discuss how these pathways provide therapeutic targets in metabolic disorders.
Details
; Langin Dominique 4
1 Institute of Metabolic and Cardiovascular Diseases (I2MC), Institut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France (GRID:grid.457379.b); University of Toulouse, Paul Sabatier University, I2MC, Toulouse, France (GRID:grid.462178.e) (ISNI:0000 0004 0537 1089); Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525); Joint Heidelberg-IDC Translational Diabetes Program, Inner Medicine 1, Heidelberg University Hospital, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); German Center for Diabetes Research (DZD), Neuherberg, Germany (GRID:grid.452622.5)
2 Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (GRID:grid.418151.8) (ISNI:0000 0001 1519 6403); University of Gothenburg, The Lundberg Laboratory for Diabetes Research, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582); University of Gothenburg, Wallenberg Centre for Molecular and Translational Medicine, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582)
3 Karolinska Institutet, Department of Medicine (H7), Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
4 Institute of Metabolic and Cardiovascular Diseases (I2MC), Institut National de la Santé et de la Recherche Médicale (Inserm), Toulouse, France (GRID:grid.457379.b); University of Toulouse, Paul Sabatier University, I2MC, Toulouse, France (GRID:grid.462178.e) (ISNI:0000 0004 0537 1089); Prague and Paul Sabatier University, Franco-Czech Laboratory for Clinical Research on Obesity, Third Faculty of Medicine, Toulouse, France (GRID:grid.15781.3a) (ISNI:0000 0001 0723 035X); Toulouse University Hospitals, Laboratory of Clinical Biochemistry, Toulouse, France (GRID:grid.508721.9)





